Propanc Biopharma (PPCB) Cash & Equivalents (2015 - 2025)
Propanc Biopharma (PPCB) posted quarterly Cash & Equivalents of $602737.0 for Q3 2025, up 6403.42% year-over-year from $9268.0 in Q3 2024, and up 4886.24% quarter-over-quarter from $12088.0 in Q2 2025.
Propanc Biopharma (PPCB) Cash & Equivalents (2015 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Cash & Equivalents for 11 consecutive years, with $602737.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash & Equivalents rose 6403.42% year-over-year to $602737.0; the TTM figure through Sep 2025 stood at $602737.0 (up 6403.42% YoY), while the FY2025 annual figure was $12088.0, down 42.67% from the prior year.
- Cash & Equivalents rose to $602737.0 in Q3 2025 per PPCB's latest filing, from $12088.0 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $602737.0 in Q3 2025 and bottomed at $2255.0 in Q2 2021.
- Historically, Cash & Equivalents has averaged $60134.6 across 5 years, with a median of $17014.5 in 2022.
- Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 93.33% — and 2025, when it surged 6403.42%.
- Propanc Biopharma's Cash & Equivalents stood at $73616.0 in 2021, then plunged by 66.75% to $24476.0 in 2022, then soared by 192.74% to $71650.0 in 2023, then tumbled by 79.58% to $14633.0 in 2024, then soared by 4019.03% to $602737.0 in 2025.
- Business Quant data shows PPCB's Cash & Equivalents at $602737.0 in Q3 2025, $12088.0 in Q2 2025, and $50760.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 561,237.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 602,737.00 |
| Jun 30, 2025 | 12,088.00 |
| Mar 31, 2025 | 50,760.00 |
| Dec 31, 2024 | 14,633.00 |
| Sep 30, 2024 | 9,268.00 |
| Jun 30, 2024 | 21,085.00 |
| Mar 31, 2024 | 6,222.00 |
| Dec 31, 2023 | 71,650.00 |
| Sep 30, 2023 | 6,625.00 |
| Jun 30, 2023 | 10,047.00 |
| Mar 31, 2023 | 93,241.00 |
| Dec 31, 2022 | 24,476.00 |
| Sep 30, 2022 | 19,396.00 |
| Jun 30, 2022 | 4,067.00 |
| Dec 31, 2021 | 73,616.00 |
| Sep 30, 2021 | 45,817.00 |
| Jun 30, 2021 | 2,255.00 |
| Mar 31, 2021 | 14,439.00 |
| Dec 31, 2020 | 21,243.00 |
| Mar 31, 2020 | 26,957.00 |